Neogen Chemicals Limited reported a standalone net profit of ₹19.44 crore for the quarter ended June 30, 2026, marking a 36.6% increase from ₹14.23 crore in the corresponding period of the previous year. Revenue from operations rose to ₹252.28 crore from ₹184.58 crore, driven by higher material consumption and inventory adjustments. The Board also granted in-principle approval to raise up to ₹600 crore through equity or debt instruments, signaling strategic capital deployment plans despite a recent credit rating downgrade by Crisil Ratings Limited.

The financial results were approved by the Board at its meeting held on July 24, 2026, and reviewed by statutory auditors Chandabhoy & Jassoobhoy. The company confirmed no deviation in the utilization of funds raised through its preferential issue of equity shares earlier in the year. Additionally, the Board appointed CNK & Associates as the internal auditor for FY27 and set August 13, 2026, as the record date for determining eligibility for remote e-voting and final dividend entitlements at the upcoming 37th Annual General Meeting.

Financial Performance Highlights

On a consolidated basis, net profit stood at ₹17.11 crore against ₹10.26 crore in Q1FY25. Consolidated revenue from operations increased to ₹250.29 crore from ₹186.73 crore. The operating margin improved to 19.35% from 15.96%, reflecting better cost management and operational efficiency post-recovery from the March 2025 fire incident at its Dahej SEZ plant.

Capital Structure and Rating Update

Crisil Ratings Limited downgraded Neogen Chemicals’ long-term rating from 'A/Negative' to 'A-/Negative' and short-term rating from 'A1' to 'A2' on July 17, 2026. Consequently, the coupon rate on its outstanding ₹200 crore Non-Convertible Debentures (NCDs) increased from 10.50% per annum to 11.00% per annum effective immediately. Despite the downgrade, the security coverage ratio for the NCDs remained robust at 2.27 times as of June 30, 2026.

The Board authorized raising funds up to ₹600 crore in Indian or foreign currency via Qualified Institutional Placements (QIP), preferential allotment, or other eligible securities. This move aims to strengthen the balance sheet and support growth initiatives across its specialty chemicals and battery chemicals segments.

Insurance Claim Recovery Status

The company continues to recover from the fire incident at its Dahej plant on March 5, 2025. As of June 30, 2026, Neogen Chemicals had received ₹149.38 crore towards insurance claims and scrap sales against a recognized loss of ₹348.16 crore. An additional ₹15 crore was received subsequent to the quarter-end, reducing the outstanding claim receivable to ₹171.63 crore. Management maintains that the remaining balance is fully recoverable.

What the Numbers Show

The divergence between standalone and consolidated margins highlights the impact of inter-segment transactions and subsidiary performance. While standalone operating margins expanded by 84 basis points to 19.09%, consolidated margins saw a sharper improvement to 19.35% from 15.96%. This suggests that subsidiaries are contributing more efficiently to the group’s overall profitability. However, the rising finance costs—up to ₹23.10 crore from ₹14.03 crore year-on-year—indicate increased leverage, partly due to the new NCD issuance. Investors should monitor whether the planned ₹600 crore fund raise will be deployed to reduce interest burden or expand capacity, given the recent rating downgrade.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE136S01016/41e7ef07-3010-4812-9731-b7fd182a208b.pdf

Neogen Chemicals has received approval to raise ₹6 billion through a Qualified Institutional Placement (QIP), marking a significant capital-raising milestone for the specialty chemicals company.

Capital Raise Details

The following table outlines the key details of the approved fundraising initiative:

About the QIP Route

A Qualified Institutional Placement is a capital-raising mechanism that enables listed companies to issue equity shares or securities to qualified institutional buyers. This route is widely used by Indian-listed companies as it offers a relatively faster and more streamlined process for raising funds compared to other public offering methods, without requiring a separate prospectus filing with the market regulator.

Neogen Chemicals' approval to raise ₹6 billion through this instrument underscores the company's intent to access institutional capital markets for its funding requirements.